Charles River Laboratories International, Inc.CRL
NYSE•Healthcare•Diagnostics & Research
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $4.03B, growing 0.1% year-over-year. TTM net income stood at $-184.65M (630.2% contraction). Quarterly EBITDA was $187.05M and operating income was $119.90M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze CRL growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters